| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
Boc-Nva-OH, as a synthetic intermediate, has no biological target. Its role is to provide norvaline residues in peptide chains. It does not interact with enzymes or receptors in pharmacological assays. Its "target" is the peptide coupling reaction, where it acts as a protected amino acid donor. The presence of L-norvaline introduces a four-carbon aliphatic side chain into the peptide structure, which can significantly alter the peptide's physicochemical properties and biological activity compared to valine-containing peptides. The Boc protecting group strategy enables selective reactions during peptide chain assembly, preventing unwanted side reactions. The compound's utility lies entirely in the chemical synthesis domain rather than in pharmacological evaluation. In solid-phase peptide synthesis, the Boc group is typically removed with TFA between coupling steps, allowing for the controlled assembly of peptide chains.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of Boc-Nva-OH is measured by coupling efficiency in solid-phase or solution-phase synthesis. Typically, it reacts with resin-bound or free amines using standard coupling reagents such as HBTU/HOBt/DIEA. Coupling yields >90% are common with this building block. Purity is assessed by HPLC (typically ≥98%) and TLC. No inherent biological activity is observed as the compound is a protected amino acid derivative intended for synthetic purposes. The compound's reactivity is characterized by the successful formation of peptide bonds with various amino acid derivatives under standard SPPS conditions. Quality control includes assessment of appearance (white to slight yellow to beige powder), identity (IR), optical rotation, purity by TLC (≥98%), and solubility in DMF. The compound is a standard building block for Boc SPPS. |
| ln Vivo |
In vivo activity is not applicable for Boc-Nva-OH. The compound is not used in animals and is a research chemical for laboratory synthesis only. It is not intended for therapeutic or diagnostic purposes. Any biological activity that might be observed would be a result of metabolic conversion following deprotection, but such studies are not typically conducted with this protected amino acid. Its utility lies entirely in the chemical synthesis domain rather than in pharmacological evaluation. The compound is stored and handled under standard laboratory conditions for chemical synthesis.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for Boc-Nva-OH involves standard peptide synthesis and characterization procedures. A typical workflow: dissolve Boc-Nva-OH (1 equiv.) in DMF, add HBTU (1.1 equiv.), HOBt (1.1 equiv.), and DIEA (2 equiv.), then add amine component. Stir at room temperature for 2-3 hours. Monitor by TLC (ninhydrin). After work-up, purify by flash chromatography. Characterize by ¹H-NMR (Boc tert-butyl at δ 1.4, norvaline side chain) and MS ([M+H]⁺). The compound's use as a standard building block for introduction of norvaline amino-acid residues by Boc SPPS is well established. Associated protocols and technical articles for cleavage and deprotection protocols for Boc SPPS are available. TLC solvent systems for Novabiochem products are documented. The compound has an optical rotation α 25/D (c=2 in methanol) of -16.5 to -13.5°.
|
| Cell Assay |
In vitro cell-based experimental workflows are not performed on Boc-Nva-OH. The deprotected norvaline-containing peptides may be tested in cell viability or receptor binding assays, but the protected compound itself is not used in cell-based systems. The compound is strictly a synthetic intermediate and is not intended for biological activity screening. When incorporated into peptides, the final deprotected products may be subjected to standard cell-based assays including cell viability (MTT assay), apoptosis detection, or receptor binding studies depending on the biological target of the synthesized peptide. However, these assays are performed on the final peptide products rather than the protected amino acid building block.
|
| Animal Protocol |
In vivo animal experiments are not relevant for Boc-Nva-OH. The compound is a synthetic intermediate and is not used in animal models. It is stored at 2-8°C. The compound is not formulated for any route of administration. Any in vivo studies would involve the final deprotected peptide products rather than the protected amino acid itself.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Boc-Nva-OH have not been characterized. The compound is not a drug. It has moderate lipophilicity (LogP ~1.5) but no ADME data are available. The compound is stable under recommended storage conditions. If administered, the Boc protecting group would likely be cleaved metabolically, releasing norvaline, but such studies are not conducted with this protected amino acid. No data on absorption, distribution, metabolism, or excretion are available for the protected form.
|
| Toxicity/Toxicokinetics |
The toxicological data for Boc-Nva-OH are limited. Standard precautions apply: it may cause skin and eye irritation, avoid dust inhalation. No chronic, carcinogenic, or reproductive toxicity studies exist because it is not a pharmaceutical. Handle in fume hood with appropriate personal protective equipment. Not approved for human or veterinary use. The compound is intended for research use only.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Boc-Nva-OH is a common reagent for introducing norvaline into peptides. It is a standard building block for introduction of norvaline amino-acid residues by Boc SPPS. The compound is commercially available from multiple suppliers including Novabiochem®. It is not a drug and has no clinical status. The compound has a purity of ≥98% (TLC) and is available in powder form. The product line is Novabiochem® and the manufacturer/tradename is Novabiochem®. The compound is used in peptide synthesis applications. Replaces: 04-12-0107. Novabiochem is a registered trademark of Merck KGaA. The compound has a storage temperature of 2-8°C. The compound is classified as WGK 3.
|
| Molecular Formula |
C10H19NO4
|
|---|---|
| Molecular Weight |
217.26
|
| Exact Mass |
217.131
|
| CAS # |
53308-95-5
|
| PubChem CID |
2733748
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
348.3±25.0 °C at 760 mmHg
|
| Melting Point |
43-47ºC
|
| Flash Point |
164.4±23.2 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.462
|
| LogP |
2.16
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
15
|
| Complexity |
232
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCC[C@@H](C(=O)O)NC(=O)OC(C)(C)C
|
| InChi Key |
INWOAUUPYIXDHN-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C10H19NO4/c1-5-6-7(8(12)13)11-9(14)15-10(2,3)4/h7H,5-6H2,1-4H3,(H,11,14)(H,12,13)/t7-/m0/s1
|
| Chemical Name |
(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6028 mL | 23.0139 mL | 46.0278 mL | |
| 5 mM | 0.9206 mL | 4.6028 mL | 9.2056 mL | |
| 10 mM | 0.4603 mL | 2.3014 mL | 4.6028 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
